DocWire News Editors

DocwireNews

β-thalassemia is a blood disorder that reduces the production of hemoglobin. It is an inherited hemoglobinopathy associated with an erythroid maturation defect characterized by ineffective erythropoiesis and impaired maturation of red blood cells (RBCs). In people with β&#8211;thalassemia, low levels of hemoglobin lead to a lack of oxygen in many parts of the body.
Luspatercept is a new agent under development to treat β-thalassemia. At the ASH annual meeting, a group of international researchers from the BELIEVE trial, a phase III, randomized, double-blind, placebo-controlled study, presented data showing that treatment with luspatercept led to significant reductions in RBC transfusion burden in adults with transfusion-dependent β-thalassemia. Lead author Maria Domenica Cappellini, MD, of Milan, Italy, collaborated with an international team of coauthors.
The study enrolled, randomized, and treated 336 patients who were 18 years or older, had β-thalassemia or hemoglobin (Hb) E/β‑thalassemia, required regular transfusions of 6–20 RBC units in the 24 weeks prior to randomization, and had no transfusion-free period of 35 days or longer during those 24 weeks. The sample’s median age was 30 years (range 18–66), and 58% of patients were female.
The researchers randomized subjects (2:1) to receive luspatercept or placebo every three weeks for at least 48 weeks. Patients in both treatment arms continued to receive RBC transfusions and iron chelation therapy. The primary endpoint was a reduction in transfusion burden of 33% or more during weeks 13–24, as compared to the 12-week baseline.
In the luspatercept group, 48 of 224 (21.4%) patients reached the primary endpoint; in the placebo group, 5 of 112 (4.5%) did so. At weeks 37–48, 44 of 224 (19.6%) patients receiving luspatercept achieved a 33% or better reduction in RBC transfusion burden, compared with 4 of 112 (3.6%) patients receiving placebo. The researchers also evaluated a 50% or better reduction in RBC transfusion burden at 13–24 and 37–48 weeks. They found that patients receiving luspatercept had rates of 7.6% and 10.3%, compared with 1.8% and 0.9% of those on placebo, respectively.
Patients experienced adverse events similar to those reported in the phase II trial, and treatment-emergent adverse events that led to dose delays or reductions were similar between both groups. No deaths occurred among patients receiving luspatercept.
The authors concluded that treatment with luspatercept significantly reduced RBC transfusion burden in adults with transfusion-dependent β-thalassemia, observing that luspatercept was well tolerated in their patient population.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

BELIEVE Trial: Luspatercept Reduces Transfusion Burden in β-Thalassemia

ASH Annual Meeting 2018

β-thalassemia is a blood disorder that reduces the production of hemoglobin. It is an inherited hemoglobinopathy associated with an erythroid maturation defect characterized ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe